DexCom's growth rate has been accelerating for multiple quarters, and recently came in at around 22%. A rise in GLP-1 drugs has some investors concerned that DexCom's growth opportunities may be ...
For the first time in a decade, DexcomDXCM has a new chief executive. And, to say Jake Leach has his work cut out for him is underselling it. Dexcom stock toppled almost 15% in 2025, pulling back ...
It's been a tough year for DexCom (NASDAQ: DXCM), whose stock price is down 25% since the start of 2025. It's a surprising performance, given that the overall stock market has been doing well; you ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results